key: cord-0323371-p6hjyf7t authors: Chen, Judy; Deng, Jane C.; Zemans, Rachel; Zhang, Min; Peters-Golden, Marc; Goldstein, Daniel R. title: Age-elevated prostaglandin E2 enhances mortality to influenza infection date: 2021-12-03 journal: bioRxiv DOI: 10.1101/2021.12.02.470775 sha: a23d7f72add92f66b28ab0caaac3ca1c2f7330f6 doc_id: 323371 cord_uid: p6hjyf7t Aging impairs the immune responses to influenza A virus (IAV), resulting in increased mortality to IAV infections in older adults. With aging, there is reduced number and impaired function of alveolar macrophages (AMs), cells critical for defense against IAV. However, factors within the aged lung that impair AMs are not fully known. Using a murine model of IAV infection, we observed that aging increased the level of prostaglandin E2 (PGE2) in the bronchoalveolar lavage fluid (BALF) of aged mice compared to young mice. Blockade of the PGE2 receptor EP2 in aged mice increased AM numbers and subsequently enhanced survival to IAV. Additionally, PGE2 impaired the mitochondrial health of AMs. We also identified senescent type II alveolar epithelial cells (AECs) as a source of the aged-associated PGE2 in the lung. Our results reveal a crosstalk between AECs and AMs, via PGE2, that compromises host defense to IAV infection with aging. susceptibility is of increasing concern as the average age of the world's population 42 continues to increase, especially in developed countries (United Nations, 2020). individuals and the emergence of IAV strains that are resistant to these treatments will 47 limit their future use (Cooper et al., 2003; Uyeki et al., 2019) . Given the limitations of the 48 current therapies and the increasing burden of IAV in older adults, we need to 49 understand the consequences of aging on the immune response against IAV so that we 50 can develop novel age-specific therapies. 51 We have previously examined the effects of aging on alveolar macrophages 52 (AMs), the sentinel airspace and airway resident macrophages that are the first 53 responders to respiratory pathogens and play a key role in maintaining homeostasis of 54 the lungs. The importance of AMs in the control of an IAV infection is best evidenced by 55 age, increased production of SASP factors contribute to inflammaging, the low-grade, 94 chronic, sterile inflammation associated with aging (Franceschi and Campisi, 2014; 95 Franceschi et al., 2018) . 96 Here, we employed murine models and show that PGE2 levels increased within 97 the lung alveolar space with aging. We revealed that PGE2,through the EP2 receptor, 98 limits AM proliferation and mitochondrial fitness with aging, and most importantly PGE2 99 reduces survival of aged mice to lethal IAV infection. Additionally, we identified 100 senescent type II alveolar epithelial cells (AECs) to be a contributor to age-associated 101 6 elevations of PGE2 in the lung. Our study has revealed a pathophysiological relationship 102 between type II AECs and AMs via elevated PGE2 that impairs host defense to IAV with 103 aging. Aging increases PGE2 levels in the lung before and after IAV infection. 107 To begin to interrogate the role of PGE2 in respiratory health and host defense 108 with aging, we first measured PGE2 levels in the plasma of young (2-4 months) and 109 aged (18-22 months) female non-infected C57BL/6 mice by ELISA. We observed a ~2-110 fold increase in PGE2 concentration in aged mice as compared to young mice 111 (Supplemental Figure 1A) , confirming that aging indicates that aging leads to increased 112 systemic levels of PGE2. 113 Next, we measured levels of PGE2 within the bronchoalveolar lavage fluid (BALF) 114 of young and aged female non-infected C57BL/6 mice. We observed a ~2-fold increase 115 of PGE2 in the BALF of aged mice compared to young mice ( Figure 1A ). To confirm that 116 this finding is not genotype-or sex-specific, we also measured PGE2 in the BALF of 117 young (6 months) and aged (22 months) male non-infected UM-HET3 mice, a 4-way 118 crossed outbred mouse strain used by the National Institute on Aging Interventions 119 Testing Program (Miller et al., 2007) . Similar to the female C57BL/6 mice, the aged 120 male UM-HET3 exhibited an ~3-fold increase of PGE2 within the BALF compared to the 121 young mice ( Figure 1B ). How aging impacts PGE2 levels within the BALF during respiratory viral 123 infections, in particular IAV, remains to be elucidated. To examine this, we infected 124 young and aged female C57BL/6 mice with 400 plaque forming units (pfu) of IAV 125 intranasally (i.n.) as 400 pfu is the lethal dose 70% (LD70) in aged mice (Supplemental 126 Figure 1B , survival tracked up to 15 days post infection (dpi)). Note, for all subsequent 127 infections, female mice were used and infected with 400 pfu, unless otherwise stated). The BALF was then collected from the mice at 0, 1, 3, 6, and 8 dpi. IAV infection 129 increased PGE2 levels within the BALF in both young and aged mice ( Figure 1C ). Notably, aged mice exhibited ~4-5 -fold higher levels of PGE2 within the BALF as 131 compared to young mice by 8 dpi. Overall, these results indicate that PGE2 levels 132 increase after IAV infection, and this increase is exacerbated by aging. Aging reduces the number of AMs in female C57BL/6 mice (Wong et al., 2017) . 137 We confirmed this age-associated phenotype is not sex-or strain-specific by 138 enumerating AMs in the BALF of young and aged male UM-HET3 mice (Supplemental 139 Figure 2A ). 140 We recently showed that PGE2 limits AM proliferation in vitro through the PGE2 approach. Non-infected aged C57BL/6 mice were i.p. injected daily with the EP2 146 antagonist or vehicle control for 7 days. We collected the BALF and enumerated AMs 147 (defined as CD45 + CD11c + SiglecF + ) by flow cytometry. Blocking PGE2 signaling 148 through the EP2 receptor increased total AM numbers by ~1.3-fold in aged mice ( Figure 149 2A). In contrast, blocking the EP2 receptor in young C57BL/6 mice failed to alter total 150 AM numbers (Supplemental Figure 2C ). These results suggest that PGE2 signaling 151 becomes aberrant with aging and limits AM numbers. Increased proliferation and/or reduced apoptosis could explain the increase in 153 AM number. To determine if blocking the PGE2 receptor EP2 increases AM cell 154 numbers through proliferation, aged mice treated with the EP2 antagonist or vehicle 155 control were also administered BrdU, a thymidine analog that is incorporated into newly 156 synthesized DNA of proliferating cells (Cameron, 2006) . Flow cytometry analysis 157 revealed that blocking the EP2 receptor in aged mice led to a ~2-fold increase in the 158 percent of BrdU positive AMs compared to the control ( Figure 2B ). To assess if blocking 159 PGE2 signaling alters apoptosis of AMs, we stained AMs from aged mice treated with 160 EP2 antagonist or vehicle control with Annexin V and analyzed via flow cytometry. Our 161 results indicated that EP2 receptor blockade does not affect AM apoptosis ( Figure 2C ). Overall, these results show that PGE2 limits AM numbers with aging, via the EP2 163 receptor, by reducing AM proliferation and without altering apoptosis. To determine if aging alters the expression of the EP2 receptor on AMs, we re- (TMM) normalized counts from the RNA-seq dataset showed no age-associated 168 differences in expression of the EP2 receptors on AMs on a transcriptomic level 169 (Supplemental Figure 2D ). This indicates that the differential response of EP2 170 antagonism in young versus aged mice is independent of altered expression of the EP2 171 receptor. Figure 2C ). Therefore, excessive PGE2 signaling limits both AM numbers and 209 compromises survival to IAV in an age-dependent manner. 210 We next examined if EP2 blockade could alter the clinical response to IAV in 211 aged mice when the blockade is administered during active infection. Therefore, we 212 infected aged C57BL/6 mice with IAV and administered 7 daily i.p. injections of the EP2 213 receptor antagonist, or vehicle control, starting on the day of infection (Supplemental 214 Figure 3F ). We found no differences in survival between the treated and control mice There were no differences in total CD45 + hematopoietic cell numbers (Supplemental 254 Figure 4G ), percentage of CD4 + T cells (CD3 + CD4 + CD8 -) (Supplemental Figure 4H ) 255 within the total T cell population, B cells (CD45 + B220 + ) (Supplemental Figure 4I ) within 256 the CD45 + population, or total monocytes/macrophages (CD45 + F4/80 + ) (Supplemental 257 Figure 4J ) within the lung. vehicle control treated mice). We found that when AMs from aged MitoQc mice were 305 compared to AMs from young MitoQC mice, aged AMs exhibited a reduced mitophagy 306 index ( Figure 5E ). We next determine if PGE2 is an age-associated factor that limits 307 mitophagy in AMs, by treating middle-aged (i.e., 9-10 months) non-infected MitoQC 308 mice with seven daily doses of the EP2 antagonist. When we compared EP2 antagonist 309 treated mice to vehicle control, we found that blocking the EP2 receptor increased To determine whether AMs or type II AECs are a predominant source of PGE2 348 with aging, we isolated and cultured both AMs and type II AECs from non-infected 349 young and aged mice. Following 2 days of culture, the cell culture medium was 350 collected and analyzed for PGE2 by ELISA. Type II AECs produced PGE2 at 3 orders of 351 magnitude higher than AMs ( Figure 6A ). Importantly, type II AECs from aged mice 352 produced about 2-fold more PGE2 than type II AECs from young mice ( Figure 6A ). These results suggest that type II AECs, not AMs, are a major source of PGE2 in the 354 BALF before infection, and aging increases the production of PGE2 by type II AECs. 355 We next determined if IAV infection increases PGE2 production by type II AECs 356 and whether aging exacerbates the phenotype. Hence, we cultured type II AECs 357 isolated from either young or aged mice and infected the AECs in vitro with IAV at a 358 multiplicity of infection (MOI) of 0.1 for 2 days. We subsequently measured PGE2 in the 359 culture supernatants via ELISA. Importantly, IAV led to increased PGE2 production by 360 ~1.5-fold in both young and aged AECs, but infected type II AECs from aged mice still 361 produced ~2-fold higher levels of PGE2 as compared to infected type II AECs isolated 362 from young mice ( Figure 6B ). Senescence is sufficient to increase PGE2 production by type II AECs. 365 Next, we sought to determine a cellular mechanism by which aging increases 366 PGE2 production by type II AECs. One of the hallmarks of aging is cellular senescence, and if PGE2 is a SASP factor, we first characterized whether type II AECs from aged 372 mice exhibit features of senescence. Hence, we measured the secretion of two SASP 373 factors, IL-6 and TNF-α from type II AECs isolated from non-infected young and aged 374 mice ( Figure 6C-D) . Notably, type II AECs from non-infected aged mice exhibited a ~2-3 375 fold increased secretion of both IL-6 and TNF-α as compared to type II AECs from non-376 infected young mice. Additionally, we measured the senescence marker p21 in young 377 and aged type II AEC lysates by western blot ( Figure 6E ). Type II AECs from non-378 infected young mice had undetectable levels of p21, whereas type II AECs from non-379 infected aged mice exhibited marked expression of p21. Overall, these results show that 380 type II AECs isolated from non-infected aged mice exhibit evidence of senescence. To determine if senescence is sufficient to increase PGE2 secretion, we 382 irradiated type II AECs isolated from young mice to induce a senescent phenotype Figure 6B ). Together, these results suggest that PGE2 is a 391 SASP factor of senescent type II AECs, and that senescent type II AECs are a major 392 producer of PGE2 with aging. Our study demonstrates that blocking PGE2 function via inhibiting the EP2 receptor is 416 sufficient to increase AM numbers via increased proliferation in non-infected aged mice. aging. 436 We also found that whereas EP2 receptor blockade increased AM numbers in Employing a mitophagy reporter mice, our study has found that activation of the EP2 459 receptor, the major PGE2 receptor on AMs, limits mitophagy in AMs. Our study found 460 that EP2 receptor blockade reduces mitochondrial mass, mitochondrial oxidative stress 461 and mitochondrial membrane potential in AMs, which could be explained by EP2 462 receptor blockade increasing mitophagy. Our study also shows that PGE2 restricts both consequences thereof, will require future investigation. 468 We identified senescent type II AECs as a predominant cellular source of 469 elevated PGE2 in the aged lung. Our study suggests that with aging, type II AECs In conclusion, our study has revealed that age-associated overproduction of 501 PGE2 in the lung, largely by senescent type II alveolar epithelial cells, impairs AM 502 proliferation, and reduces total AM cell numbers. This limits the ability of AMs to defend 503 against IAV infection. Additionally, our study shows that PGE2 impairs mitophagy and 504 mitochondrial health of AMs (graphically represented in Figure 7) . Thus, we have 505 identified a novel, aberrant form of cross talk between type II AECs and AMs, via the 506 secretion of PGE2, that restrains AM numbers to compromise host defense to IAV 507 infection with aging. Additionally, our study suggests that potential therapies that target 508 senescent type II AECs and their production of PGE2 or the EP2-mediated signaling in PGE2 suppression of innate immunity 603 during mucosal bacterial infection Prostaglandin E2 Inhibits Alveolar Macrophage Phagocytosis through an E-Prostanoid 2 Receptor-Mediated 606 Increase in Intracellular Cyclic AMP Immunosenescence: emerging challenges 608 for an ageing population Arachidonic acid 610 metabolism in cultured alveolar macrophages from normal, atopic, and asthmatic 611 subjects An Essential Role of the Mitochondrial Electron Transport Chain in Cell 614 Proliferation Is to Enable Aspartate Synthesis Quantitative analysis of in vivo cell proliferation Alveolar Macrophages Prevent Lethal Influenza Pneumonia By Inhibiting Infection Of Type-1 Alveolar Epithelial 619 Cells Estimated Flu-Related Illnesses Medical Visits, Hospitalizations, and Deaths in the United States -2017 Mitophagy: An Emerging Role in Aging 624 and Age-Associated Diseases. Front Role of Aging and the Immune 626 Response to Respiratory Viral Infections: Potential Implications for COVID-19 | The 627 Journal of Immunology The burden of respiratory infections among 630 older adults in long-term care: a systematic review Mitochondrial metabolism and the 633 control of vascular smooth muscle cell proliferation. Front Prostaglandin E2 promotes features of replicative senescence in chronically activated 636 human CD8+ T cells Effectiveness of neuraminidase inhibitors in treatment and prevention of 639 influenza A and B: systematic review and meta-analyses of randomised controlled 640 trials Targeted prostaglandin E2 643 inhibition enhances antiviral immunity through induction of type I interferon and 644 apoptosis in macrophages Epithelial repair mechanisms in the lung Prostaglandin E2 Reduces Toll-Like Receptor 4 Expression in Alveolar Macrophages by 649 Inhibition of Translation Cellular 651 senescence in ageing: from mechanisms to therapeutic opportunities Bacterial Pneumonia in the Elderly In vitro and in vivo characterization of PF-04418948, a novel, potent and 657 selective prostaglandin EP₂ receptor antagonist Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases Inflammaging: a new immune-metabolic viewpoint for age-related diseases Depletion of Alveolar 664 Macrophages during Influenza Infection Facilitates Bacterial Superinfections Monocyte Recruitment into the Lungs in Pneumococcal Pneumonia Regulation of prostaglandin synthase-1 and 670 prostaglandin synthase-2 Alveolar macrophages: plasticity in a tissue-specific 672 context PARK2-mediated mitophagy is involved 675 in regulation of HBEC senescence in COPD pathogenesis Estimates of global 678 seasonal influenza-associated respiratory mortality: a modelling study Alveolar macrophages have a protective anti 682 inflammatory role during murine pneumococcal pneumonia Mechanisms of Cellular Senescence: Cell Cycle Arrest 685 and Senescence Associated Secretory Phenotype. Front Ionizing Radiation-Induced Cellular 687 Non-transformed Cells and the Involved DNA Damage 688 Response: A Mini Review Mitophagy in Parkinson's Disease: From 690 Pathogenesis to Treatment The 692 Hallmarks of Cellular senescence involves an intracrine prostaglandin E2 695 pathway in human fibroblasts MH-S, a murine alveolar macrophage cell 697 line: morphological, cytochemical, and functional characteristics The role of prostaglandin E2 700 receptors in the pathogenesis of rheumatoid arthritis The lung microenvironment shapes a 703 dysfunctional response of alveolar macrophages in aging mito-QC illuminates mitophagy and 706 mitochondrial architecture in vivo An aging Interventions 709 Testing Program: study design and interim report Restoring metabolism of 712 myeloid cells reverses cognitive decline in ageing Multifaceted roles of PGE2 in inflammation 714 and cancer Mechanisms of mitophagy in 716 cellular homeostasis, physiology and pathology PGE2 accounts for 719 bidirectional changes in alveolar macrophage self-renewal with aging and smoking Alliance 3 Prostaglandins and Inflammation Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 726 disease Single-cell RNA sequencing identifies TGFb as a key regenerative cue following LPS-induced lung injury edgeR: a Bioconductor 732 package for differential expression analysis of digital gene expression data Prostaglandin E2 As a Modulator of 735 Viral Infections Phenotypic and functional heterogeneity of 737 the murine alveolar macrophage-derived cell line MH-S Tracking the Spatial and Functional Gradient of Monocyte-To-Macrophage 740 Differentiation in Inflamed Lung Serves as a Request Signal for Macrophage Secretion of Suppressor of Signaling 3 during Innate Inflammation Targeting mitochondrial dysfunction in lung 746 diseases: emphasis on mitophagy Influenza-Associated Hospitalizations in the United States Age-Associated Mitochondrial Dysfunction Accelerates Atherogenesis World population ageing Age and Sex Composition Practice Guidelines by the Infectious Diseases Society of America Treatment, Chemoprophylaxis, and Institutional Outbreak Management of 759 Seasonal Influenzaa Critical role of phospholipase A2 group IID in age-related 762 susceptibility to severe acute respiratory syndrome-CoV infection Host Cell Restriction Factors that Limit Influenza A Infection Influenza A 768 viruses target type II pneumocytes in the human lung Metformin 771 inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis Respiratory epithelial cells orchestrate 774 pulmonary innate immunity Regulation of Macrophage Cytokine Production 776 by Prostaglandin E2 Aging Impairs Alveolar Macrophage Phagocytosis and Increases Influenza-779 Induced Mortality in Mice Resistance to Acute Macrophage Killing 782 Promotes Airway Fitness of Prevalent Community-Acquired Staphylococcus aureus 783 Neutrophil transmigration 786 triggers repair of the lung epithelium via β-catenin signaling Mitochondria regulate intestinal stem cell 789 proliferation and epithelial homeostasis through FOXO Measuring energy 792 metabolism in cultured cells, including human pluripotent stem cells and differentiated 793 cells primary type II AECs and AMs in culture. Statistical significance analyzed by ANOVA 871 with Tukey post-hoc test. (B) Primary type II AECs were isolated from young and aged 872 C57BL/6 mice and were infected ex-vivo with PR8 IAV (MOI = 0.1). Cell culture media 873 was collected following 2 days of accumulation and analyzed for PGE2 with ELISA.